Patient-reported Outcomes in the Treatment of Schizophrenia

This study has been completed.
Information provided by:
Solvay Pharmaceuticals Identifier:
First received: September 12, 2005
Last updated: September 11, 2013
Last verified: September 2007
Patient-reported health economic outcomes for patients enrolled in S1543003 and S1543004 protocols

Condition Intervention Phase
Drug: bifeprunox
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Patient-reported Outcomes With Bifeprunox or Olanzapine in the Treatment of Schizophrenia. A Pharmacoeconomic Study Carried Out in Connection With the S1543003 And S1543004 Clinical Trials

Resource links provided by NLM:

Further study details as provided by Solvay Pharmaceuticals:

Study Start Date: May 2005
Primary Completion Date: January 2006 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Participate in S1543003 and S1543004 in the U.S. sites

Exclusion Criteria:

  • Participate in S1543003 and S1543004 other than U.S. sites
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00230828

Sponsors and Collaborators
Solvay Pharmaceuticals
Study Director: Global Clinical Director Solvay Solvay Pharmaceuticals
  More Information Identifier: NCT00230828     History of Changes
Other Study ID Numbers: S154.3.005 
Study First Received: September 12, 2005
Last Updated: September 11, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Mental Disorders
Schizophrenia Spectrum and Other Psychotic Disorders processed this record on May 26, 2016